Clinical Trial Update: Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy)) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for NRTX-1001 neural cell therapy in drug-resistant unilateral mesial temporal lobe epilepsy; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mesial Temporal Lobe Epilepsy

Drugs mentioned

• NRTX-1001 (NRTX-1001)

Snippet

Sponsor: Neurona Therapeutics | Conditions: Mesial Temporal Lobe Epilepsy | Phase 3 | Status: RECRUITING